NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Alterity Therapeutics Ltd. ATHE
10 fiscal years on record · AUD · FY2024 reported · SEC filings only
AUD -12.1M
Growth
—
Revenue, FY2024 · full 10-year series below
Revenue AUD M
Net income AUD M
FY2017 · Revenue 0.2 · Net income -8.3
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
Operating margin
Net margin
FY2017 · Net -4108.8%
ROE
No chart to show — the reason differs by year; see each year in the table below.
The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · AUD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue AUD B | · | · | · | · | · | · | · | 0.0 | 0.0 | 0.0 |
| Operating income AUD B | · | · | · | · | · | · | · | · | · | · |
| EBITDA AUD B | · | · | · | · | · | · | · | · | · | · |
| Income tax AUD B | 0.0 | 0.0 | 0.0 | 0.0 | · | · | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income AUD B | −0.0 | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow AUD B | · | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted AUD | −0.19 | −0.52 | −0.57 | −0.53 | −0.90 | −1.50 | −2.00 | · | · | · |
| Dividend / sh AUD | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | · |
| Shares out B | · | · | 2.44 | 2.41 | 2.08 | · | · | · | · | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 6 failures in 34 reconciliationsAUDITED
Reconciled in 4 of 19 fiscal years. 42 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente6 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code C3
Fiscal year endsJune 30
Data on record since2015